PTGX

40.39

1.75% -0.72

Dopo l'orario di chiusura: 39.00 -1.39 -3.44%

Protagonist Therapeutics Inc (PTGX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PTGX Giù? Forum Previsione

Precedente Chiudi:

$41.11

Aprire:

$40.98

Volume 24 ore:

476.55K

Relative Volume:

0.82

Capitalizzazione di mercato:

$2.41B

Reddito:

$45.48M

Utile/perdita netta:

$169.95M

Rapporto P/E:

-15.07

EPS:

-2.68

Flusso di cassa netto:

$230.85M

1 W Prestazione:

-13.14%

1M Prestazione:

-14.01%

6M Prestazione:

+31.39%

1 anno Prestazione:

+140.27%

Intervallo 1D:

$39.70

$41.05

Intervallo di 1 settimana:

$39.41

$46.64

Portata 52W:

$16.63

$48.89

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Nome

Protagonist Therapeutics Inc

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

(510) 474-0170

Indirizzo

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Dipendente

126

Cinguettio

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

PTGX's Discussions on Twitter

Confronta PTGX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PTGX	40.39	2.41B	45.48M	169.95M	230.85M	-2.68
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-05-25	Ripresa	Jefferies	Buy
2022-08-25	Iniziato	JMP Securities	Mkt Outperform
2022-02-11	Iniziato	BTIG Research	Buy
2021-10-12	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-11	Aggiornamento	Northland Capital	Market Perform → Outperform
2021-09-20	Downgrade	JP Morgan	Overweight → Neutral
2021-05-24	Iniziato	JMP Securities	Mkt Outperform
2021-05-24	Iniziato	Northland Capital	Outperform
2021-01-06	Iniziato	JP Morgan	Overweight
2020-12-16	Iniziato	Piper Sandler	Overweight
2020-09-18	Reiterato	H.C. Wainwright	Buy
2020-07-15	Iniziato	Jefferies	Buy
2020-05-18	Reiterato	H.C. Wainwright	Buy
2019-07-08	Iniziato	H.C. Wainwright	Buy
2019-05-09	Aggiornamento	Stifel	Hold → Buy
2018-12-06	Iniziato	Nomura	Buy
2018-01-29	Iniziato	Stifel	Buy
2017-07-21	Iniziato	BTIG Research	Buy

Mostra tutto

Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie

Nov 18, 2024

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis - WSIL TV

Nov 18, 2024

Protagonist Therapeutics Enters Oversold Territory (PTGX) - Nasdaq

Nov 18, 2024

Protagonist's Psoriasis Drug Shows 74% Success Rate, Secures $165M Milestone Payment | PTGX Stock News - StockTitan

Nov 18, 2024

Nov 17, 2024

Janney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 17, 2024

Nov 16, 2024

Amalgamated Bank Buys 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 16, 2024

Nov 15, 2024

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Nov 13, 2024

HC Wainwright Issues Pessimistic Estimate for PTGX Earnings - MarketBeat

Nov 13, 2024

US Bancorp DE Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 13, 2024

Nov 11, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Nov 10, 2024

New York State Teachers Retirement System Invests $1.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 10, 2024

New York State Teachers Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 10, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High – Should You Buy? - Defense World

Nov 10, 2024

Nov 09, 2024

Creative Planning Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 09, 2024

Nov 08, 2024

What is Wedbush’s Forecast for PTGX Q3 Earnings? - Defense World

Nov 08, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighWhat's Next? - MarketBeat

Nov 08, 2024

Protagonist Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK

Nov 08, 2024

Nov 07, 2024

What is Wedbush's Estimate for PTGX Q3 Earnings? - MarketBeat

Nov 07, 2024